Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
24 02 2021
Historique:
received: 19 05 2020
accepted: 13 01 2021
entrez: 25 2 2021
pubmed: 26 2 2021
medline: 4 3 2021
Statut: epublish

Résumé

Telomere maintenance by telomerase activation or alternative lengthening of telomeres (ALT) is a major determinant of poor outcome in neuroblastoma. Here, we screen for ALT in primary and relapsed neuroblastomas (n = 760) and characterize its features using multi-omics profiling. ALT-positive tumors are molecularly distinct from other neuroblastoma subtypes and enriched in a population-based clinical sequencing study cohort for relapsed cases. They display reduced ATRX/DAXX complex abundance, due to either ATRX mutations (55%) or low protein expression. The heterochromatic histone mark H3K9me3 recognized by ATRX is enriched at the telomeres of ALT-positive tumors. Notably, we find a high frequency of telomeric repeat loci with a neuroblastoma ALT-specific hotspot on chr1q42.2 and loss of the adjacent chromosomal segment forming a neo-telomere. ALT-positive neuroblastomas proliferate slowly, which is reflected by a protracted clinical course of disease. Nevertheless, children with an ALT-positive neuroblastoma have dismal outcome.

Identifiants

pubmed: 33627664
doi: 10.1038/s41467-021-21247-8
pii: 10.1038/s41467-021-21247-8
pmc: PMC7904810
doi:

Substances chimiques

Proteome 0
X-linked Nuclear Protein EC 3.6.4.12

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1269

Références

Science. 2011 Mar 4;331(6021):1199-203
pubmed: 21252315
Genome Biol. 2014;15(12):550
pubmed: 25516281
Nat Biotechnol. 2009 Dec;27(12):1181-5
pubmed: 19935656
Nat Rev Cancer. 2006 Feb;6(2):99-106
pubmed: 16491069
Nat Protoc. 2008;3(6):1032-45
pubmed: 18536650
Nat Commun. 2020 Feb 14;11(1):913
pubmed: 32060267
Nat Rev Genet. 2020 Oct;21(10):630-644
pubmed: 32709985
Cell. 2015 Feb 26;160(5):913-927
pubmed: 25723166
Cell Syst. 2020 Feb 26;10(2):125-132
pubmed: 32105631
Genes Dev. 2010 Jun 15;24(12):1253-65
pubmed: 20504901
Am J Med Genet. 1995 Jan 30;55(3):288-99
pubmed: 7726225
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
J Biotechnol. 2017 Nov 10;261:53-62
pubmed: 28803971
Rapid Commun Mass Spectrom. 1999;13(5):344-9
pubmed: 10209872
Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5
pubmed: 27079975
Nat Protoc. 2013 Mar;8(3):539-54
pubmed: 23429716
Nat Commun. 2020 Feb 5;11(1):733
pubmed: 32024817
Nat Genet. 2013 Mar;45(3):279-84
pubmed: 23334666
PLoS Genet. 2012;8(7):e1002772
pubmed: 22829774
Oncotarget. 2015 Jun 30;6(18):16543-58
pubmed: 26001292
Mol Cytogenet. 2015 May 13;8:32
pubmed: 25969696
Children (Basel). 2019 Feb 11;6(2):
pubmed: 30754710
Nat Commun. 2015 Jul 06;6:7538
pubmed: 26143912
Lancet Oncol. 2003 Aug;4(8):472-80
pubmed: 12901961
Nat Methods. 2014 Mar;11(3):319-24
pubmed: 24487582
Nucleic Acids Res. 2014 Apr;42(7):4391-405
pubmed: 24500201
Nature. 1990 Aug 30;346(6287):868-71
pubmed: 1975428
Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7
pubmed: 10430922
Sci Adv. 2019 May 08;5(5):eaav3673
pubmed: 31086817
Cell Syst. 2017 Sep 27;5(3):237-250.e8
pubmed: 28843484
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Nucleic Acids Res. 2018 Mar 16;46(5):2347-2355
pubmed: 29361030
Nature. 2005 Sep 15;437(7057):436-9
pubmed: 16079795
Nature. 2017 Jul 19;547(7663):311-317
pubmed: 28726821
Mol Cell. 2018 Aug 2;71(3):443-457
pubmed: 30075143
Cancer Res. 2006 Apr 1;66(7):3673-80
pubmed: 16585193
Nucleic Acids Res. 2019 Sep 5;47(15):7734-7752
pubmed: 31350900
Cell. 2016 Oct 20;167(3):803-815.e21
pubmed: 27720452
BMC Genomics. 2012 Nov 15;13:630
pubmed: 23153121
Trends Genet. 2014 Mar;30(3):85-94
pubmed: 24503142
BMC Genet. 2018 May 18;19(1):32
pubmed: 29776332
Nature. 2012 Feb 22;483(7391):589-93
pubmed: 22367537
Methods Mol Biol. 2010;659:71-82
pubmed: 20809304
Med Pediatr Oncol. 2001 Dec;37(6):492-504
pubmed: 11745887
Cell. 2012 Jul 6;150(1):39-52
pubmed: 22748632
Eur J Cancer. 2016 Sep;65:91-101
pubmed: 27479119
Cell. 2001 Nov 2;107(3):323-37
pubmed: 11701123
Nature. 2000 Aug 10;406(6796):593-9
pubmed: 10949293
Nat Rev Dis Primers. 2016 Nov 10;2:16078
pubmed: 27830764
Nat Genet. 2017 Mar;49(3):349-357
pubmed: 28135248
JAMA. 2012 Mar 14;307(10):1062-71
pubmed: 22416102
Nat Rev Cancer. 2003 Mar;3(3):203-16
pubmed: 12612655
Oncogene. 1999 Sep 2;18(35):4948-57
pubmed: 10490829
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Science. 2011 Jul 22;333(6041):425
pubmed: 21719641
Bioinformatics. 2009 Aug 1;25(15):1952-8
pubmed: 19505939
Nat Genet. 2018 Apr;50(4):515-523
pubmed: 29379199
Cancer Res. 2020 Jun 15;80(12):2663-2675
pubmed: 32291317
Lancet Oncol. 2017 Apr;18(4):500-514
pubmed: 28259608
N Engl J Med. 2005 Nov 24;353(21):2243-53
pubmed: 16306521
Proc Natl Acad Sci U S A. 2010 Aug 10;107(32):14075-80
pubmed: 20651253
BMC Bioinformatics. 2019 May 28;20(1):272
pubmed: 31138115
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Am J Hum Genet. 1994 Sep;55(3):505-12
pubmed: 7521575
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21
pubmed: 11309499
Genome Res. 2012 Oct;22(10):2008-17
pubmed: 22722343
Cell. 2008 Sep 19;134(6):981-94
pubmed: 18805091
Nature. 2012 Jan 29;482(7384):226-31
pubmed: 22286061
Nature. 2015 Oct 29;526(7575):700-4
pubmed: 26466568
Science. 2018 Dec 7;362(6419):1165-1170
pubmed: 30523111
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
J Clin Oncol. 1999 Jul;17(7):2264-79
pubmed: 10561284
Cell. 2010 Mar 5;140(5):678-91
pubmed: 20211137
Clin Cancer Res. 2017 Aug 1;23(15):4224-4232
pubmed: 28228384
Eur J Hum Genet. 2007 Oct;15(10):1094-7
pubmed: 17579672
Eur J Cancer. 1995;31A(4):637-41
pubmed: 7576985
Nat Struct Mol Biol. 2012 Sep;19(9):948-56
pubmed: 22922742
Bioinformatics. 2015 Jun 15;31(12):2032-4
pubmed: 25697820
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427
Nature. 2008 Oct 9;455(7214):770-4
pubmed: 18806779

Auteurs

Sabine A Hartlieb (SA)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.

Lina Sieverling (L)

Faculty of Biosciences, Heidelberg University, Heidelberg, Germany.
Applied Bioinformatics, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg, Germany.

Michal Nadler-Holly (M)

Proteome Dynamics, Max Delbrück Center for Molecular Medicine, Berlin, Germany.

Matthias Ziehm (M)

Proteome Dynamics, Max Delbrück Center for Molecular Medicine, Berlin, Germany.

Umut H Toprak (UH)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Carl Herrmann (C)

Health Data Science Unit, Medical Faculty Heidelberg and BioQuant, Heidelberg, Germany.

Naveed Ishaque (N)

Digital Health Centre, Berlin Institute of Health (BIH), Berlin, Germany.
Charité - Universitätsmedizin Berlin, Berlin, Germany.

Konstantin Okonechnikov (K)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Moritz Gartlgruber (M)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Young-Gyu Park (YG)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Elisa Maria Wecht (EM)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Larissa Savelyeva (L)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Kai-Oliver Henrich (KO)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Carolina Rosswog (C)

Department of Experimental Pediatric Oncology, University Children's Hospital of Cologne, Medical Faculty, Cologne, Germany.

Matthias Fischer (M)

Department of Experimental Pediatric Oncology, University Children's Hospital of Cologne, Medical Faculty, Cologne, Germany.
Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
Department of Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany.

Barbara Hero (B)

Department of Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany.

David T W Jones (DTW)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Pediatric Glioma Research Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Elke Pfaff (E)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Pediatric Hematology and Oncology, University Hospital, Heidelberg, Germany.

Olaf Witt (O)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Department of Pediatric Hematology and Oncology, University Hospital, Heidelberg, Germany.
Clinical Cooperation Unit Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Stefan M Pfister (SM)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Pediatric Hematology and Oncology, University Hospital, Heidelberg, Germany.

Richard Volckmann (R)

Department of Oncogenomics Amsterdam University Medical Centers (AUMC), Amsterdam, the Netherlands.

Jan Koster (J)

Department of Oncogenomics Amsterdam University Medical Centers (AUMC), Amsterdam, the Netherlands.

Katharina Kiesel (K)

Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany.

Karsten Rippe (K)

Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany.

Sabine Taschner-Mandl (S)

CCRI, St Anna Children's Cancer Research Institute, Vienna, Austria.

Peter Ambros (P)

CCRI, St Anna Children's Cancer Research Institute, Vienna, Austria.

Benedikt Brors (B)

Applied Bioinformatics, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.

Matthias Selbach (M)

Proteome Dynamics, Max Delbrück Center for Molecular Medicine, Berlin, Germany.
Charité - Universitätsmedizin Berlin, Berlin, Germany.

Lars Feuerbach (L)

Applied Bioinformatics, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.

Frank Westermann (F)

Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany. f.westermann@kitz-heidelberg.de.
Neuroblastoma Genomics, German Cancer Research Center (DKFZ), Heidelberg, Germany. f.westermann@kitz-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH